Antiobesity and vasoprotective effects of resveratrol in ApoE-deficient mice

Journal of Medicinal Food

Volumn 17, Issue 3, 2014, Pages 310-316

  Jeon, Seon Min ^a   Lee, Seung A ^a   Choi, Myung Sook ^a  

^a Kyungpook National University   (South Korea)

Author keywords

apoE deficient mice; body fat; lipid metabolism; resveratrol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CARNITINE PALMITOYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE; FAT DROPLET; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RESVERATROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; EPIDIDYMIS FAT; FATTY ACID OXIDATION; FOOD INTAKE; HISTOPATHOLOGY; HYPERLIPIDEMIA; HYPOLIPEMIA; LIPID LIVER LEVEL; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; OBESITY; ORGAN WEIGHT; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; ANTI-OBESITY AGENTS; ANTICHOLESTEREMIC AGENTS; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; DIET, ATHEROGENIC; HUMANS; LOVASTATIN; MALE; MICE; MICE, KNOCKOUT; OBESITY; PROTECTIVE AGENTS; STILBENES;

EID: 84896983199     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2013.2885     Document Type: Article

References (55)

1. Gylling H: Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int J Clin Pract 2004;58:859-866.
2. Walldius G, Jungner I, Holme I, et al.: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-2033.
3. Srinivasan SR, Berenson GS: Apolipoproteins B and A-I as predictors of risk of coronary artery disease. Lancet 2001;358: 2012-2013.
4. Jeon SM, Park YB, Choi MS: Antihypercholesterolemic property of naringin alters plasma and tissue lipids, cholesterol-regulating enzymes, fecal sterol and tissue morphology in rabbits. Clin Nutr 2004;23:1025-1034.
5. Woo MN, Jeon SM, Kim HJ, et al.: Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentration in high-fat fed C57BL/6N mice. Chem Biol Interact 2010;186:316-322.
6. Miatello R, Vázquez M, Renna N, et al.: Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005;18:864-870.
7. Dal-Pan A, Blanc S, Aujard F: Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol 2010;10:11.
8. Ramadori G, Gautron L, Fujikawa T, et al.: Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009; 150:5326-5333.
9. Choi HY, Chong SA, Nam MJ: Resveratrol induces apoptosis in human SK-HEP-1 hepatic cancer cells. Cancer Genomics Pro-teomics 2009;6:263-268.
10. Fischer-Posovszky P, Kukulus V, Tews D, et al.: Resveratrol regulates human adipocyte number and function in a Sirt1-de-pendent manner. Am J Clin Nutr 2010;92:5-15.
11. Valenzano DR, Terzibasi E, Genade T, et al.: Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006;16:296-300.
12. Kervinen K, Savolainen MJ, Heikkilä JI, et al.: Lovastatin enhances hepatic uptake of low density lipoprotein in humans. J Lipid Res 1993;34:1975-1982.
13. Nakashima Y, Plump AS, Raines EW, et al.: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994;14:133-140.
14. Kato M, Sada T, Chuma H, et al.: Severity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor antagonist in apolipoprotein E-deficient mice. J Cardi-ovasc Pharmacol 2006;47:764-769.
15. Folch J, Lees M, Sloan-Stanley GH: A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
16. Hulcher FH, Oleson WH: Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res 1973;14:625-631.
17. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
18. Nepokroeff CM, Lakshmanan MR, Porter JW: Fatty-acid syn-thase from rat liver. Methods Enzymol 1975;35:37-44.
19. Ochoa S: Malic enzyme: malic enzymes from pigeon and wheat germ. In: Methods in Enzymology (Colowick SP, Kaplan NO, eds.). Academic Press, New York, 1995, pp. 323-326.
20. Pitkanen E, Pitkanen O, Uotila L: Enzymatic determination of unbound D-mannose in serum. Eur J Clin Chem Clin Biochem 1997;35:761-766.
21. 2+-dependent phosphatidate phos-phohydrolase of rat lung: development of an assay employing a defined chemical substrate which reflects the phosphohydrolase activity measured using membrane-bound substrate. Anal Bio-chem 1985;151:479-486.
22. Markwell MAK, McGroarty EJ, Bieber LL, et al.: The subcel-lular distribution of carnitine acyltransferases in mammalian liver and kidney. J Biol Chem 1973;248:3426-3432.
23. Lazarow PB: Assay of peroxisomal b-oxidation of fatty acids. Method Enzymol 1981;72:315-319.
24. Shapiro DJ, Nordstrom JL, Mitschelen JJ: Microassay for 3-hydroxy-3-methyl glutaryl CoA reductase in rat liver and in L-cell fibroblast. Biochim Biophys Acta 1974;370:369-377.
25. Gillies PJ, Rathgeb KA, Robinson CS: Regulation of acyl-CoA:cholesterol acyltransferase activity in normal and atherosclerotic rabbit aortas: Role of a cholesterol substrate pool. Exp Mol Pathol 1986;44:320-339.
26. Paigen B, Plump AS, Rubin EM: The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr Opin Lipidol 1994;5:258-264.
27. Macarulla MT, Alberdi G, Gómez S, et al.: Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J Physiol Biochem 2009;65:369-376.
28. Rivera L, Morón R, Zarzuelo A, et al.: Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009;77: 1053-1063.
29. Shang J, Chen LL, Xiao FX: Resveratrol improves high-fat induced nonalcoholic fatty liver in rats. Zhonghua Gan Zang Bing Za Zhi 2008;16:616-619.
30. Cho IJ, Ahn JY, Kim S, et al.: Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun 2008;367:190-194.
31. Soleas GJ, Diamandis EP, Goldberg DM: Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997;30: 91-113.
32. Goldberg DM, Hahn SE, Parkes JG: Beyond alcohol: beverage consumption and cardiovascular mortality. Clin Chem Acta 1995; 237:155-187.
33. Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J 2007;22:659-661.
34. Penumathsa SV, Thirunavukkarasu M, Koneru S, et al.: Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 2007;42:508-516.
35. Sacks FM, Tonkin AM, Shepherd J, et al.: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-1900.
36. Grundy SM, Hansen B, Smith SC Jr, et al.: American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551-556.
37. Do GM, Kwon EY, Kim HJ, et al.: Long-term effects of re-sveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008;374:55-59.
38. Ingelsson E, Massaro JM, Sutherland P, et al.: Contemporary trends in dyslipidemia in the Framingham Heart Study. Arch Intern Med 2009;169:279-286.
39. Aubin MC, Lajoie C, Clément R, et al.: Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 2008; 325:961-968.
40. Baur JA, Pearson KJ, Price NL, et al.: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337-342.
41. Xu H, Xu HE, Ryan D: A study of the comparative effects of hawthorn fruit compound and simvastatin on lowering blood li-pid levels. Am J Chin Med 2009;37:903-908.
42. Steinmetz EF, Buckley C, Shames ML, et al.: Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005;241:92-101.
43. Rayalam S, Yang JY, Ambati S, et al.: Resveratrol induces ap-optosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phyt-other Res 2008;22:1367-1371.
44. Park HJ, Yang JY, Ambati S, et al.: Combined effects of gen-istein, quercetin, and resveratrol in human and 3T3-L1 adipo-cytes. J Med Food 2008;11:773-783.
45. Gnoni GV, Paglialonga G: Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes. Eur J Clin Invest 2009;39:211-218.
46. Penumathsa SV, Thirunavukkarasu M, Zhan L, et al.: Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med 2008;12:2350-2361.
47. Hardie DG, Pan DA: Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002;30:1064-1070.
48. Pallottini V, Montanari L, Cavallini G, et al.: Mechanisms underlying the impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in aged rat liver. Mech Ageing Dev 2004; 125:633-639.
49. Poulsen MM, Larsen JØ, Hamilton-Dutoit S, et al.: Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr Res 2012;32:701-708.
50. Seifalian AM, Piasecki C, Agarwal A, et al.: The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999;68:780-784.
51. Kinlay S, Libby P, Ganz P: Endothelial function and coronary artery disease. Curr Opin Lipidol 2001;12:383-389.
52. Ekshyyan VP, Hebert VY, Khandelwal A, et al.: Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardio-vasc Pharmacol 2007;50:83-93.
53. Park DW, Baek K, Kim JR, et al.: Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med 2009;41:171-179.
54. Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravas-tatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-844.
55. Delanty N, Vaughan CJ: Vascular effects of statins in stroke. Stroke 1997;28:2315-2320.